New drug-radiation combo tested for tough breast cancer

NCT ID NCT03542175

First seen Nov 01, 2025 · Last updated May 09, 2026 · Updated 23 times

Summary

This early-phase study tested the safety of adding the drug rucaparib to standard radiation therapy for women with triple negative breast cancer who still had cancer after chemotherapy. 31 women participated. The main goal was to find safe dose levels and watch for side effects. This is not a cure, but aims to improve treatment options.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Memorial Sloan Kettering Bergen

    Montvale, New Jersey, 07645, United States

  • Memorial Sloan Kettering Cancer Center

    New York, New York, 10065, United States

  • Memorial Sloan Kettering Commack

    Commack, New York, 11725, United States

  • Memorial Sloan Kettering Monmouth

    Middletown, New Jersey, 07748, United States

  • Memorial Sloan Kettering Nassau

    Uniondale, New York, 11553, United States

  • Memorial Sloan Kettering Westchester

    Harrison, New York, 10604, United States

  • Memorial Sloan Kettering at Basking Ridge

    Basking Ridge, New Jersey, 07920, United States

  • Norwalk Hospital

    Norwalk, Connecticut, 06850, United States

Conditions

Explore the condition pages connected to this study.